Day-one subcutaneous Leqembi lets eligible patients with early Alzheimer's start anti-amyloid treatment with a weekly skin injection instead of IV infusions. Anti-amyloid treatment is medicine that clears amyloid-beta protein buildup tied to Alzheimer's, and Leqembi Iqlik is lecanemab-irmb in autoinjector form. According to the Eisai/Biogen news release, FDA approved this initiation use on July 13-14, 2026, as the first anti-amyloid treatment usable under the skin from day one Eisai/Biogen approval notice. Use the questions below to confirm eligibility, dosing, safety monitoring, and cost at a specialist visit.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Are you eligible to start?
- What does weekly treatment look like?
- How will the clinic watch for brain swelling or bleeding?
- What should you ask about genes and payment?
Are you eligible to start?
Treatment is only for adults with early disease. That means mild cognitive impairment or mild dementia due to Alzheimer's, with amyloid confirmed by PET scan or spinal-fluid testing.
Ask your specialist what stage your symptoms match and which test proves amyloid in your case. According to the Eisai/Biogen availability notice shared by JCN Newswire, confirmation by PET or spinal fluid is required before initiation. Bring prior memory scores, brain scans, and spinal-fluid results.
- Ask: is my diagnosis mild cognitive impairment or mild dementia due to Alzheimer's?
- Ask: have I had PET or spinal-fluid testing that shows amyloid?
- Ask: do blood thinners, prior brain bleeds, or other conditions rule me out?
What does weekly treatment look like?
The initiation regimen is 500 mg once weekly, given as two 250-mg autoinjector injections of about 15 seconds each, as reported by PharmExec from the Eisai release PharmExec report on the Eisai release. After 18 months, some patients may switch to 360 mg weekly maintenance.
The product moves through specialty pharmacy as a weekly autoinjector, not over the counter. Ask who will train you, how to store pens, what to do after a missed dose, and when the clinic will review whether maintenance fits.
How will the clinic watch for brain swelling or bleeding?
Leqembi carries a boxed warning for amyloid-related imaging abnormalities, called ARIA. ARIA means brain swelling or bleeding that is usually without symptoms but can cause seizure, hospitalization, or death, according to the FDA prescribing-information summary shared by Alzheimer Europe FDA prescribing-information summary.
FDA recommended an extra earlier brain MRI before the third infusion in August 2025, plus routine MRI checks during initiation. Ask for your MRI dates, who reads the scans, and what symptoms trigger an urgent call.
- Ask: when are my baseline and follow-up MRIs scheduled?
- Ask: what headache, confusion, vision change, dizziness, or weakness needs same-day care?
- Ask: will treatment pause if swelling or bleeding appears?
What should you ask about genes and payment?
Northwestern Medicine physician guidance advises ApoE epsilon-4 genetic testing before starting. Carriers face higher ARIA frequency and severity, especially people with two copies, so specialists may decline treatment or offer stronger counseling for homozygotes. Practical cost matters too.
According to Managed Healthcare Executive, Leqembi Iqlik initiation lists at $385 per autoinjector, or $770 per week, while IV coverage runs under Medicare Part B with registry enrollment and Iqlik coverage varies Managed Healthcare Executive cost report. Part D out-of-pocket is capped around $2,000 per year. Bring your insurance card, ask whether your plan covers Iqlik initiation, and ask which specialty pharmacy will dispense it.
You Might Also Like
- Tauklarify Tau PET vs Alzheimer’s Blood Tests in 2026: Questions Younger-Onset Alzheimer’s Families Can Bring to a Clinician
- Tauklarify Tau PET vs Amyloid PET After the 2026 Approval: Questions Younger-Onset Alzheimer’s Families Can Bring to a Clinician
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: Accuracy, Limits, and Evidence Gaps for Younger-Onset Alzheimer’s Families
